Impact of Ministerial Decree 77/2022 from different stakeholders’ perspectives: clinicians, pharmacists, patients, and industry
Global and Regional Health Technology Assessment · 19.06.2026 · 13 (1) · 156-166
DOI: 10.33393/grhta.2026.3664 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global and Regional Health Technology Assessment, online erschienen am 19.06.2026. Verfasst von Guido Attilio Condorelli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Centre in the Medical-Pharmaceutical Field, Department of Pharmaceutical Science, Faculty of Medicine and Pharmacy, "Dunarea de Jos" Univers…. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Assess the implications of Ministerial Decree (MD) 77/2022 in Italy, which decentralizes healthcarethrough proximity-based models, from the perspective of key actors involved, and discuss its relevance to sustainability and value assessment.
Methods
A cross-sectional survey was conducted with four stakeholder groups: pharmaceutical companies, scientific societies, Health Economics and Outcomes Research (HEOR) experts, and patient advocacy organizations(N = 162). Structured questionnaires examined awareness/knowledge, perceived implementation, perceived impact, operational feasibility, and policy alignment.
Results
Over 60% of respondents recognized the strategic value of proximity care. Key barriers included administrative burden (47%), resource constraints (38%), and lack of Key Performance Indicator (KPI)-based frameworks (55%). Treatments in oncology, geriatrics, and metabolic diseases were considered most suitable for decentralized provision. Divergent perspectives emerged professional stakeholders emphasized methodological rigour and outcome monitoring, while patient organizations foregrounded equity of access, responsiveness, and patient-facing feasibility.
Conclusion
MD 77/2022 opens a policy window to align decentralized care pathways with sustainability andvalue assessment. However, the survey did not collect empirical pricing, reimbursement, or cost-effectivenessdata; therefore, any implications for pricing governance should be interpreted as conceptual and hypothesisgenerating rather than as demonstrated effects. Heterogeneous implementation and fragmented outcome measurement remain the primary barriers; a minimum viable KPI set and routine data infrastructure are prerequisites for translating perceived value into decision-relevant evidence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Centre in the Medical-Pharmaceutical Field, Department of Pharmaceutical Science, Faculty of Medicine and Pharmacy, "Dunarea de Jos" University of Galati, Galati - Romania.
- Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania - Italy.
- Department of Legal Studies, University of Salento, Lecce - Italy.
- Abiogen Pharma S.p.A., Pisa - Italy.
- Department of Pharmaceutical Science (DISFARM), University of Milan, Milan - Italy.
- Roche S.p.A., Monza - Italy.
ORCID-Profile: Guido Attilio Condorelli, Martina Pipoli, Deborah Bonifacio, Andrea Marcellusi, Laura Paganoni
Zitieren
APA
Condorelli, G. A., Pipoli, M., Bonifacio, D., Marcellusi, A., & Paganoni, L. (2026). Impact of Ministerial Decree 77/2022 from different stakeholders’ perspectives: clinicians, pharmacists, patients, and industry. Global and Regional Health Technology Assessment, 13(1), 156-166. https://doi.org/10.33393/grhta.2026.3664
Vancouver
Condorelli GA, Pipoli M, Bonifacio D, Marcellusi A, Paganoni L. Impact of Ministerial Decree 77/2022 from different stakeholders’ perspectives: clinicians, pharmacists, patients, and industry. Global and Regional Health Technology Assessment. 2026;13(1):156-166. doi:10.33393/grhta.2026.3664
BibTeX
@article{Condorelli2026,
author = {Condorelli, Guido Attilio and Pipoli, Martina and Bonifacio, Deborah and Marcellusi, Andrea and Paganoni, Laura},
title = {Impact of Ministerial Decree 77/2022 from different stakeholders’ perspectives: clinicians, pharmacists, patients, and industry},
journal = {Global and Regional Health Technology Assessment},
year = {2026},
volume = {13},
number = {1},
pages = {156--166},
doi = {10.33393/grhta.2026.3664}
}
EUVIMED